Assessment of the knowledge of health professionals about preventive pharmacotherapy for COVID-19
DOI:
https://doi.org/10.33448/rsd-v11i12.34141Keywords:
COVID-19; Health Care Professionals; SARS-CoV-2.Abstract
Since its emergence in 2019, SARS-CoV-2 has proved to be very versatile and lethal. The numbers of deaths and hospitalizations have become a problem, therefore, it is necessary to find a measure against the infection. Therefore, new studies have emerged from existing drugs, such as Hydroxychloroquine, Nitazoxanide, Azithromycin and Ivermectin. However, amidst the uncertainties, the use of these drugs was widespread, even after carrying out studies that did not find the real benefit of this therapy, becoming a problem, especially in Brazil. Therefore, the present study sought to understand the perspective of health professionals, from an electronic form, in relation to early treatment as well as preventive measures for COVID-19. Regarding early treatment, most individuals (69/88) do not believe in the use of drugs as a prophylactic or cure, and those over 39 years of age had higher confidence levels (40% and 28%) in this pharmacological management in relation to professionals aged between 18 and 39 years (14.3% and 1.6%). When asked about the safety and efficacy of vaccines, professionals with a technical level had a lower confidence index (82.4%) when compared to those with a higher level (97.2%). The data indicate that health professionals tend to seek updates on COVID-19, but that specific groups should receive attention, aiming to combat misinformation and fully implement the concept of evidence-based health.
References
Arévalo, A., Pagotto, R., Pórfido, J., Daghero, H., Segovia, M., Yamasaki, K., Varela, B., Hill, M., Verdes, J., Duhalde Vega, M., Bollati-Fogolín, M., & Crispo, M. (2020). Ivermectin reduces coronavirus infection in vivo: A mouse experimental model [Preprint]. Pathology. doi: 10.1101/2020.11.02.363242
Atallah, A. N. (2018). Medicina baseada em evidências. Diagnóstico & Tratamento, 23(2), 43-4. Recuperado de: https://www.associacaopaulistamedicina.org.br/assets/uploads/old/revista_rdt/3633b0e2b787dc55a3433cda35f10dfc.pdf#page=5
Brasil, Ministério da Saúde (2021a). Nitazoxanida para prevenção e tratamento de pacientes com Covid-19. Recuperado de: https://www.gov.br/saude/pt-br/coronavirus/publicacoes-tecnicas/notas-tecnicas/nota-tenica-nitazoxanida-covid-19
Brasil, Ministério da Saúde. (2020b). Orientações do Ministério da Saúde para manuseio medicamentoso precoce de pacientes com diagnóstico da Covid-19. Recuperado de: https://www.gov.br/saude/pt-br/centrais-de-conteudo/arquivos/orientacoes-manuseio-medicamentoso-covid19-pdf#:~:text=Cloroquina%20deve%20ser%20evitada%20em,anticoagula%C3%A7%C3%A3o%20e%20pulsoterapia%20com%20cortic%C3%B3ide.
Brasil, Ministério da Saúde (2022). Coronavírus Brasil. Recuperado de: https://covid.saude.gov.br/
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 178, 104787. doi: 10.1016/j.antiviral.2020.104787
Carvalho C. R. R.; Falavigna M. & coordenadores (2021). Orientações sobre o tratamento farmacológico do paciente adulto hospitalizado com COVID-19. Recuperado de: https://www.gov.br/ebserh/pt-br/hospitais-universitarios/regiao-sul/hu-ufsc/comunicacao/noticias/MS_TratamentofarmacologicoCOVID_2021.pdf
Dias, V. M. C. H., Carneiro, M., Vidal, C. F. L., Corradi, M. F. D. B., Brandão, D., Cunha, C. A., ... & Waib, L. F. (2020). Orientações sobre diagnóstico, tratamento e isolamento de pacientes com COVID-19. J Infect Control, 9(2), 56-75. Recuperado de: https://jic-abih.com.br/index.php/jic/article/view/295
Fernandes, L. de S., Calado, C., & Araujo, C. A. S. (2018). Redes sociais e práticas em saúde: Influência de uma comunidade online de diabetes na adesão ao tratamento. Ciência & Saúde Coletiva, 23(10), 3357–3368. doi: 10.1590/1413-812320182310.14122018
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J.-M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 56(1), 105949. doi: 10.1016/j.ijantimicag.2020.105949
Junior, K. R. de C. (2020). Here we go again: The reemergence of anti-vaccine activism on the Internet. Cadernos de Saúde Pública, 36(suppl 2), e00037620. doi: 10.1590/0102-311x00037620
López-Medina, E., López, P., Hurtado, I. C., Dávalos, D. M., Ramirez, O., Martínez, E., Díazgranados, J. A., Oñate, J. M., Chavarriaga, H., Herrera, S., Parra, B., Libreros, G., Jaramillo, R., Avendaño, A. C., Toro, D. F., Torres, M., Lesmes, M. C., Rios, C. A., & Caicedo, I. (2021). Effect of ivermectin on time to resolution of symptoms among adults with mild covid-19: A randomized clinical trial. JAMA, 325(14), 1426. doi: 10.1001/jama.2021.3071
Melo, J. R. R., Duarte, E. C., Moraes, M. V. de, Fleck, K., & Arrais, P. S. D. (2021a). Automedicação e uso indiscriminado de medicamentos durante a pandemia da COVID-19. Cadernos de Saúde Pública, 37(4), e00053221. doi: 10.1590/0102-311x00053221
Melo, J. R. R., Duarte, E. C., Moraes, M. V. de, Fleck, K., Silva, A. S. do N. e, & Arrais, P. S. D. (2021b). Reações adversas a medicamentos em pacientes com COVID-19 no Brasil: Análise das notificações espontâneas do sistema de farmacovigilância brasileiro. Cadernos de Saúde Pública, 37(1), e00245820. doi: 10.1590/0102-311x00245820
MITJÀ, O. et al. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. New England Journal of Medicine, v. 384, n. 5, p. 417–427. Disponivel em: doi: 10.1056/NEJMoa2021801
Oliveira, W. de S., Migueis, G. da S., Silva, M. S. da, & Oliveira, W. J. (2021). Conhecimento sobre Covid-19 dos profissionais de enfermagem atuantes no enfrentamento da doença. Research, Society and Development, 10(11), e244101119676. doi: 10.33448/rsd-v10i11.19676
Peres, KG & Peres, MA (2010). Saúde baseada em evidências [Recurso eletrônico]. Recuperado de: http://ares.unasus.gov.br/acervo/handle/ARES/196
Reis, G., Silva, E. A. S. M., Silva, D. C. M., Thabane, L., Milagres, A. C., Ferreira, T. S., dos Santos, C. V. Q., Campos, V. H. S., Nogueira, A. M. R., de Almeida, A. P. F. G., Callegari, E. D., Neto, A. D. F., Savassi, L. C. M., Simplicio, M. I. C., Ribeiro, L. B., Oliveira, R., Harari, O., Forrest, J. I., Ruton, H., … Mills, E. J. (2022). Effect of early treatment with ivermectin among patients with covid-19. New England Journal of Medicine, 386(18), 1721–1731. doi: 10.1056/NEJMoa2115869
Rocco, P. R. M., Silva, P. L., Cruz, F. F., Melo-Junior, M. A. C., Tierno, P. F. G. M. M., Moura, M. A., De Oliveira, L. F. G., Lima, C. C., Dos Santos, E. A., Junior, W. F., Fernandes, A. P. S. M., Franchini, K. G., Magri, E., de Moraes, N. F., Gonçalves, J. M. J., Carbonieri, M. N., Dos Santos, I. S., Paes, N. F., Maciel, P. V. M., … Lapa e Silva, J. R. (2021). Early use of nitazoxanide in mild COVID-19 disease: Randomised, placebo-controlled trial. European Respiratory Journal, 58(1), 2003725. doi: 10.1183/13993003.03725-2020
Sespa. Secretaria de Saúde do Pará. (2022). Vacinômetro. Recuperado de: http://www.saude.pa.gov.br/rede-sespa/cievs/vacinometro/
Tao, K., Tzou, P.L., Nouhin, J. et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nature Reviews Genetics, 22, 757–773 (2021). doi: 10.1038/s41576-021-00408-x
UNA-SUS (2022). Coronavírus: Brasil confirma primeiro caso da doença. Recuperado de: https://www.unasus.gov.br/noticia/coronavirus-brasil-confirma-primeiro-caso-da-doenca. Acesso em: 3 fev. 2022.
YANG, Li; LIU, Shasha; LIU, Jinyan; et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduction and Targeted Therapy, v. 5, n. 1, p. 128, 2020. Doi: 10.1038/s41392-020-00243-2
ZHU, Na; ZHANG, Dingyu; WANG, Wenling; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of medicine, v. 382, n. 8, p. 727–733, 2020. doi: 10.1056/NEJMoa2001017
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Francisco Daniel Queiroz Brito; Vitor Hugo Santos da Silva; Henrique Eron da Silva Gemaque; Isis de Oliveira Kosmiscky; Letícia Azevedo Moura; Carolina Alves Duarte; Ana Beatriz dos Santos Medeiros; Karen Letícia Gonçalves de Jesus; Priscila Pessoa Diamantino Reis; José Eduardo Gomes Arruda
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
